12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Human neural stem cells: Additional Phase I data

Additional data from the open-label, U.S. Phase I CL-N01-PMD trial in 4 patients ages 14 months to 5 years with connatal PMD showed that intracerebral transplantation of HuCNS-SC was well tolerated with no reported clinical or radiological adverse events directly attributed to the cells. There were 2 serious adverse events, including a...

Read the full 240 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >